Abstract：
OBJECTIVE: This study aimed to assess the safety and efficacy of endovascular treatment of unruptured pancreatic arcade aneurysms in a single-center series.
METHODS: The electronic medical records of patients who underwent endovascular treatment for unruptured pancreatic arcade aneurysms between 2011 and 2022 at our tertiary center were retrospectively reviewed. The presence of celiac artery stenosis/occlusion; aneurysm number, location, and size; endovascular technique; procedure-related complication incidence; and clinical outcomes were assessed.
RESULTS: Twenty-three patients (12 men and 11 women; mean [range] age, 63.8 [45-84] years) with 33 unruptured pancreatic arcade aneurysms were identified. Celiac artery stenosis/occlusion coexisted in 17 (74%) patients. Five (21%) patients had multiple aneurysms. The median aneurysm size was 9.3 mm (range, 4-18 mm). Seven, 6, 6, 5, 4, 3, and 2 aneurysms were located in the gastroduodenal, dorsal pancreatic, anterior superior pancreaticoduodenal, inferior pancreaticoduodenal, posterior inferior pancreaticoduodenal, posterior superior pancreaticoduodenal, and anterior inferior pancreaticoduodenal arteries, respectively. Four (15%) and 22 (85%) aneurysms were treated with endosaccular packing alone and coil embolization with endosaccular packing and parent artery occlusion, respectively, with resulting exclusion from arterial circulation. The remaining 7 aneurysms coexisting with larger aneurysms in other peripancreatic arteries were observed without embolization because they were small and for preserving collateral blood flow to the celiac artery. The treated aneurysms did not rupture or recur during the follow-up period (median, 40 months).
CONCLUSIONS: Endovascular treatment is a safe and effective treatment for unruptured pancreatic arcade aneurysms.
METHODS: 3, non-controlled retrospective cohort study.
METHODS: The electronic medical records of patients who underwent endovascular treatment for unruptured pancreatic arcade aneurysms between 2011 and 2022 at our tertiary center were retrospectively reviewed. The presence of celiac artery stenosis/occlusion; aneurysm number, location, and size; endovascular technique; procedure-related complication incidence; and clinical outcomes were assessed.
RESULTS: Twenty-three patients (12 men and 11 women; mean [range] age, 63.8 [45-84] years) with 33 unruptured pancreatic arcade aneurysms were identified. Celiac artery stenosis/occlusion coexisted in 17 (74%) patients. Five (21%) patients had multiple aneurysms. The median aneurysm size was 9.3 mm (range, 4-18 mm). Seven, 6, 6, 5, 4, 3, and 2 aneurysms were located in the gastroduodenal, dorsal pancreatic, anterior superior pancreaticoduodenal, inferior pancreaticoduodenal, posterior inferior pancreaticoduodenal, posterior superior pancreaticoduodenal, and anterior inferior pancreaticoduodenal arteries, respectively. Four (15%) and 22 (85%) aneurysms were treated with endosaccular packing alone and coil embolization with endosaccular packing and parent artery occlusion, respectively, with resulting exclusion from arterial circulation. The remaining 7 aneurysms coexisting with larger aneurysms in other peripancreatic arteries were observed without embolization because they were small and for preserving collateral blood flow to the celiac artery. The treated aneurysms did not rupture or recur during the follow-up period (median, 40 months).
CONCLUSIONS: Endovascular treatment is a safe and effective treatment for unruptured pancreatic arcade aneurysms.
METHODS: 3, non-controlled retrospective cohort study.
摘要：
目的：本研究旨在评估单中心系列未破裂胰腺拱廊动脉瘤血管内治疗的安全性和有效性。
方法：回顾性分析了2011年至2022年在我们的三级中心接受未破裂胰腺拱廊动脉瘤血管内治疗的患者的电子病历。腹腔动脉狭窄/闭塞的存在；动脉瘤数量，location,和大小;血管内技术;手术相关并发症发生率;和临床结果进行了评估。
结果：23名患者（12名男性和11名女性；平均[范围]年龄，63.8[45-84]年），发现33个未破裂的胰腺拱廊动脉瘤。17例（74％）患者同时存在腹腔动脉狭窄/闭塞。五名（21％）患者患有多发性动脉瘤。动脉瘤的中位大小为9.3mm（范围，4-18毫米）。七,6、6、5、4、3和2个动脉瘤位于胃十二指肠，胰腺背侧,胰十二指肠前上，胰十二指肠下，后下胰十二指肠，后上胰十二指肠，和胰十二指肠下动脉，分别。4例（15％）和22例（85％）动脉瘤仅采用腔内填塞和腔内填塞和父动脉闭塞的线圈栓塞治疗，分别,导致排除动脉循环。观察到其余7个动脉瘤与其他胰周动脉中的较大动脉瘤共存，没有栓塞，因为它们很小，并且可以保留流向腹腔动脉的侧支血流。治疗的动脉瘤在随访期间没有破裂或复发（中位数，40个月）。
结论：血管内治疗是一种安全、有效的治疗未破裂胰腺拱廊动脉瘤的方法。
方法：3，非对照回顾性队列研究。
方法：回顾性分析了2011年至2022年在我们的三级中心接受未破裂胰腺拱廊动脉瘤血管内治疗的患者的电子病历。腹腔动脉狭窄/闭塞的存在；动脉瘤数量，location,和大小;血管内技术;手术相关并发症发生率;和临床结果进行了评估。
结果：23名患者（12名男性和11名女性；平均[范围]年龄，63.8[45-84]年），发现33个未破裂的胰腺拱廊动脉瘤。17例（74％）患者同时存在腹腔动脉狭窄/闭塞。五名（21％）患者患有多发性动脉瘤。动脉瘤的中位大小为9.3mm（范围，4-18毫米）。七,6、6、5、4、3和2个动脉瘤位于胃十二指肠，胰腺背侧,胰十二指肠前上，胰十二指肠下，后下胰十二指肠，后上胰十二指肠，和胰十二指肠下动脉，分别。4例（15％）和22例（85％）动脉瘤仅采用腔内填塞和腔内填塞和父动脉闭塞的线圈栓塞治疗，分别,导致排除动脉循环。观察到其余7个动脉瘤与其他胰周动脉中的较大动脉瘤共存，没有栓塞，因为它们很小，并且可以保留流向腹腔动脉的侧支血流。治疗的动脉瘤在随访期间没有破裂或复发（中位数，40个月）。
结论：血管内治疗是一种安全、有效的治疗未破裂胰腺拱廊动脉瘤的方法。
方法：3，非对照回顾性队列研究。
